MANKIND
Invest Now
Mankind Pharma Share Price
₹2,530.00 -44.4 (-1.72%)
21 Nov, 2024 14:44
Start SIP in MANKIND
Start SIPPerformance
- Low
- ₹2,515
- High
- ₹2,613
- 52 Week Low
- ₹1,821
- 52 Week High
- ₹2,874
- Open Price₹2,583
- Previous Close₹2,574
- Volume216,715
Investment Returns
- Over 1 Month -4.43%
- Over 3 Month + 7.29%
- Over 6 Month + 19.81%
- Over 1 Year + 25.69%
Smart Investing Starts Here Start SIP with Mankind Pharma for Steady Growth!
Mankind Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 47.9
- PEG Ratio
- 1.4
- Market Cap Cr
- 101,368
- P/B Ratio
- 10.6
- Average True Range
- 93.39
- EPS
- 52.79
- Dividend Yield
- 0
- MACD Signal
- 16.13
- RSI
- 46.41
- MFI
- 70.42
Mankind Pharma Financials
Mankind Pharma Technicals
EMA & SMA
Current Price
₹2,530.00
-44.4
(-1.72%)
- Bullish Moving Average 5
- Bearish Moving Average 11
- 20 Day
- ₹2,619.58
- 50 Day
- ₹2,565.40
- 100 Day
- ₹2,458.12
- 200 Day
- ₹2,300.64
Resistance and Support
2590.7
- R3 2,703.75
- R2 2,671.50
- R1 2,622.95
- S1 2,542.15
- S2 2,509.90
- S3 2,461.35
Mankind Pharma Corporate Actions - Bonus, Splits, Dividends
Date | Purpose | Remarks |
---|---|---|
2024-11-05 | Quarterly Results | |
2024-07-31 | Quarterly Results | |
2024-05-15 | Audited Results & Others | To evaluate various options or proposals for raising funds through any of the permissible modes, subject to the receipt of necessary approvals. |
2024-01-31 | Quarterly Results | |
2023-10-31 | Quarterly Results |
Mankind Pharma F&O
About Mankind Pharma
- NSE Symbol
- MANKIND
- BSE Symbol
- 543904
- ISIN
- INE634S01028
Similar Stocks to Mankind Pharma
Mankind Pharma FAQs
Mankind Pharma share price is ₹2,530 As on 21 November, 2024 | 14:30
The Market Cap of Mankind Pharma is ₹101367.5 Cr As on 21 November, 2024 | 14:30
The P/E ratio of Mankind Pharma is 47.9 As on 21 November, 2024 | 14:30
The PB ratio of Mankind Pharma is 10.6 As on 21 November, 2024 | 14:30
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.